Home・Aandelen Lijst・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Gesloten

12.89 -0.31

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

12.85

Max

12.98

Belangrijke statistieken
By Trading Economics
Inkomsten	-4.3M -18M
EPS	-0.19
Werknemers	37
EBITDA	-5.3M -17M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+128.51% upside

Dividenden
By Acuity
Volgende Winsten	3 nov 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	86M 1.2B
Vorige openingsprijs	13.2
Vorige sluitingsprijs	12.89

Corvus Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

12 sep 2026, 23:51 UTC

China's House Price Index YoY release on September 15 expected to show continued decline amid cautious market sentiment and rising global oil prices.

12 sep 2026, 23:41 UTC

Philadelphia Fed Manufacturing Index Set for Release Amid Heightened Market Sensitivity to Inflation and Interest Rate Hike Expectations.

12 sep 2026, 23:41 UTC

U.S. Building Permits Expected to Reach 1.41 Million for August Amid Mixed Housing Sentiment Ahead of September Release

12 sep 2026, 23:41 UTC

Housing Starts Data Release on September 17, 2026, Expected to Show Continued Caution Amid High Mortgage Rates and Recent Declines.

12 sep 2026, 23:41 UTC

Upcoming U.S. Building Permits Report on September 17, 2026, Expected to Reflect Economic Health Amid Stable Market Sentiment.

12 sep 2026, 23:41 UTC

Upcoming Housing Starts Data Release Amid Rising Mortgage Rates Raises Concerns for U.S. Construction Market

12 sep 2026, 23:21 UTC

U.S. Retail Sales Ex Autos Expected to Rise 0.5% in August Amid Mixed Economic Sentiment and Inflation Concerns

12 sep 2026, 23:21 UTC

U.S. Import Prices Expected to Rise 0.2% Amid Inflation Concerns and Fed Rate Speculation Following Geopolitical Tensions

12 sep 2026, 23:21 UTC

U.S. Export Prices Expected to Rise in August Amid Positive Economic Sentiment and Fed Rate Speculations

12 sep 2026, 23:21 UTC

U.S. Retail Sales Expected to Rise 0.9% in August Amid Cautious Market Sentiment Following July's Decline

12 sep 2026, 23:11 UTC

Canada's housing starts data release on September 16, 2026, expected at 235,000 units amid cautious market sentiment following July’s shortfall.

12 sep 2026, 23:01 UTC

NY Empire State Manufacturing Index Set for Release Amid Mixed Economic Sentiment and Inflation Concerns on September 15, 2026.

12 sep 2026, 23:01 UTC

Market Awaits ECB President Lagarde's Speech Amid Speculation of Future Rate Hikes and Leadership Changes Following Recent Interest Rate Increase.

12 sep 2026, 22:51 UTC

Brazil's Central Bank Set to Announce SELIC Rate Decision Amid Global Monetary Tightening and Rising Inflation Concerns on September 14, 2026.

12 sep 2026, 22:51 UTC

Japan's Core Inflation Rate Expected to Rise to 1.8% Amid Global Economic Pressures Ahead of Bank of Japan Meeting

12 sep 2026, 22:51 UTC

Japan's Upcoming Inflation Rate Report Expected to Reflect Mixed Signals Amid Rising Energy Costs and Producer Price Fluctuations

12 sep 2026, 22:41 UTC

Canada's August Inflation Rate Release on September 14 Expected to Show Continued Pressure Amid Geopolitical Tensions and Rising Oil Prices.

12 sep 2026, 22:41 UTC

Canada's Core Inflation Rate Expected to Rise to 2.4% Amid U.S. Economic Indicators and Speculation of Fed Interest Rate Hikes

12 sep 2026, 22:41 UTC

Rising U.S. 30-Year Mortgage Rates Exceed 7%, Threatening Housing Demand and Economic Growth Ahead of Key Central Bank Meetings

12 sep 2026, 22:41 UTC

Canada's Inflation Rate Expected to Hold Steady at 0.0% Amid Global Economic Concerns Ahead of September Release

12 sep 2026, 22:41 UTC

Macro News

The DAX 30 Index is lower in after-market trading, pressured by rising crude oil prices and concerns over Treasury yields and interest rate hikes.

12 sep 2026, 22:31 UTC

Japan's trade deficit forecasted at -1052.6 billion yen for August 2026 amid rising import costs and negative market sentiment.

12 sep 2026, 22:31 UTC

Japan's August Exports YoY Data Set for Release Amidst Cautious Market Sentiment and Economic Concerns

12 sep 2026, 22:31 UTC

Japan's Machinery Orders Expected to Decline Amid Market Volatility and Inflation Concerns

12 sep 2026, 22:31 UTC

Brazil's Retail Sales Report on September 15 Expected to Show Month-on-Month Growth Amid Inflationary Pressures

12 sep 2026, 22:11 UTC

Bank of England Expected to Maintain Interest Rate at 0.667% Amid Global Economic Caution and Inflation Concerns

12 sep 2026, 21:01 UTC

Oil (Brent) is trading lower during after-market hours, continuing a decline since Friday's close. The market shows weakness despite remaining above its 20-day moving average.

12 sep 2026, 21:01 UTC

India's August Inflation Rate Release on September 14 Expected at 4.8%, Amid Rising Global Energy Costs and Geopolitical Tensions

12 sep 2026, 21:01 UTC

EUR/PLN traded roughly flat during after-market hours, remaining around the middle of its one-month range with no specific news identified.

12 sep 2026, 20:51 UTC

API Crude Oil Stock Change Data Release on September 15 Expected to Show Continued Inventory Decline Amid Easing Geopolitical Tensions and Inflation Concerns.

Peer Vergelijking

Prijswijziging

Corvus Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

128.51% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 29.5 USD 128.51%

Hoogste 33 USD

Laagste 27 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Corvus Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

4 ratings

Buy

Hold

Sell

Gebaseerd op 4 analisten die aandelenratings hebben gegeven aan Corvus Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.